Davide Dvm

Davide Dvm

About

Detail

Chief Executive Officer
United States

Timeline


work
Job
school
Education

Résumé


Jobs verified_user 0% verified
  • BioAgilytix
    Chief Executive Officer
    BioAgilytix
    Nov 2023 - Current (2 years 7 months)
    BioAgilytix is the leading bioanalytical laboratory supporting pharmaceutical and biotechnology companies across all phases of drug development and manufacturing. BioAgilytix has nearly 30 years of broad experience and operates 5 bioanalytical laboratories based in different drug development hubs around the world. Its global team of more than 1000 motivated talents and over 50% PhD/master’s-level scientists averaging 10+ years of bench experience, brings expertise and scale to successfully navigate therapeutic development.
  • Summit Partners
    Executive In Residence
    Summit Partners
    Oct 2022 - Aug 2023 (11 months)
    Working alongside Summit’s healthcare & life sciences team to identify new opportunities to support growth stage companies' value creation
  • Viroclinics Biosciences BV
    Chief Executive Officer
    Viroclinics Biosciences BV
    Jul 2020 - Aug 2022 (2 years 2 months)
    Viroclinics operates at a global level, being the preferred virology testing laboratory for several of the top-10 Biopharmaceutical companies. As a virology contract research organization, Viroclinics serves the biopharmaceutical community with preclinical, clinical diagnostic, research & development, and clinical trial logistics services. The extensive experience in clinical and preclinical virology research allows the company to support the development of vaccines, antibodies and antiviral drugs targeting viral infectious diseases. Viroclinics was acquired by Cerba Healthcare in February 2022.
  • Evolution Research Group
    President and Chief Executive Officer
    Evolution Research Group
    May 2019 - Feb 2020 (10 months)
    Evolution Research Group (ERG) supports sponsors clinical development combining industry-leading experts in over 50 indications with purpose built research facilities. ERG executes complex inpatient and outpatient clinical trials in specialized populations and healthy volunteers across all age groups. The result: unparalleled support for sponsors and CROs in their quest to address the greatest unmet medical needs.
  • Charles River Laboratories
    President and Chief Operating Officer
    Charles River Laboratories
    Feb 2018 - Aug 2018 (7 months)
  • Charles River Laboratories
    Corporate EVP and President Global Research Models & Services and Preclinical Services Operations
    Charles River Laboratories
    Jan 2013 - Feb 2018 (5 years 2 months)
  • Charles River Laboratories
    Corporate EVP and President North American Operations
    Charles River Laboratories
    Jan 2011 - Jan 2013 (2 years 1 month)
  • C
    Corporate EVP and President Global Research Models & Services
    Jan 2010 - Jan 2011 (1 year 1 month)
  • Charles River Laboratories
    Corporate SVP North American and European Research Models & Services
    Charles River Laboratories
    Jan 2009 - Jan 2010 (1 year 1 month)
  • C
    Corporate VP Research Models & Services Europe
    Jan 2007 - Jan 2009 (2 years 1 month)
  • Charles River Laboratories
    Managing Director
    Charles River Laboratories
    Jan 2003 - Jan 2007 (4 years 1 month)
  • Charles River Laboratories
    Director of Operations
    Charles River Laboratories
    Jan 2002 - Jan 2004 (2 years 1 month)
  • S
    Sales and Marketing Manager
    Dec 1999 - Jan 2003 (3 years 2 months)
  • Merck
    Marketing Manager Animal Health
    Merck
    Sep 1998 - Dec 1999 (1 year 4 months)
  • Bracco
    Imaging Department Associate
    Bracco
    Mar 1997 - Sep 1998 (1 year 7 months)
  • Bracco
    Animal Care Responsible
    Bracco
    Jan 1995 - Mar 1997 (2 years 3 months)
Education verified_user 0% verified
  • Harvard Business School
    Advanced Management Program
    Harvard Business School
    Jan 2018 - Current (8 years 5 months)
  • Universita degli Studi di Milano
    VETERINARY MEDICINE, Pharmacology and Toxicology
    Universita degli Studi di Milano
    Jan 1988 - Dec 1994 (7 years)
This is a community-created genome.